Literature DB >> 21373933

HLA class-II allele frequencies in Turkish breast cancer patients.

Faik Deniz Gun1, Ozlem Goruroglu Ozturk, Ayse Polat, Gurbuz Polat.   

Abstract

Class-II human leukocyte antigens (HLA) present tumor antigenic peptides on the cell surface in order to be recognized by T lymphocytes. Thereby, these molecules can play an important role in the immune response to breast cancer tumor antigens. The aim of this study was to determine the relation between breast cancer and HLA class-II alleles in Turkey. The study groups consisted of 69 breast cancer patients and 45 healthy controls. Typing of HLA-DRB1 and HLA-DQB1 from DNA samples was performed by Sequence Specific Oligonucletide Hybridisation. Significant negative correlations were observed between HLA-DRB1 03 and HLA-DQB1 02 alleles and breast cancer (p1 = 0.019; p2 = 0.019) and also between HLA-DQB1 02 allele and postmenopausal breast cancer (P = 0.022) and c-erb-B2 positivity (P = 0.038). Furthermore, there was a significant positive correlation between HLA-DRB1 13 and HLA-DQB1 06 alleles and progesteron receptor positivity (p1 = 0.012; p2 = 0.001); and a significant negative correlation between HLA-DQB1 03 allele and progesteron receptor positivity (P = 0.009) in breast cancer. Additionally, another significant positive correlation was seen between HLA-DRB1 04 allele and c-erb-B2 positivity (P = 0.036). As a result, while HLA-DRB1 03, HLA-DQB1 02, HLA-DRB1 13, and HLA-DQB1 06 alleles were found to be involved in protectiveness against breast cancer and good prognosis; HLA-DQB1 03 and HLA-DRB1 04 alleles were found to be involved in poor prognosis. In conclusion, by determining allele types showing predisposition to breast cancer, a systematical screening and follow up systems can be developed for patients who are at high risk.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21373933     DOI: 10.1007/s12032-011-9873-4

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  26 in total

1.  Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles.

Authors:  S Chaudhuri; A Cariappa; M Tang; D Bell; D A Haber; K J Isselbacher; D Finkelstein; D Forcione; S Pillai
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

2.  Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53.

Authors:  S W Beenken; W E Grizzle; D R Crowe; M G Conner; H L Weiss; M T Sellers; H Krontiras; M M Urist; K I Bland
Journal:  Ann Surg       Date:  2001-05       Impact factor: 12.969

3.  HLA-DR and beta 2 microglobulin expression in medullary and atypical medullary carcinoma of the breast: histopathologically similar but biologically distinct entities.

Authors:  M Feinmesser; A Sulkes; S Morgenstern; J Sulkes; S Stern; E Okon
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

Review 4.  HER2 as a prognostic and predictive marker for breast cancer.

Authors:  T Cooke; J Reeves; A Lanigan; P Stanton
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

5.  HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity.

Authors:  R J Apple; H A Erlich; W Klitz; M M Manos; T M Becker; C M Wheeler
Journal:  Nat Genet       Date:  1994-02       Impact factor: 38.330

Review 6.  Gene expression profiling of breast cancer.

Authors:  Koichi Nagasaki; Yoshio Miki
Journal:  Breast Cancer       Date:  2006       Impact factor: 4.239

7.  Major histocompatibility complex status in breast carcinogenesis and relationship to apoptosis.

Authors:  Maximino Redondo; Julian García; Eduardo Villar; Isabel Rodrigo; Emilio Perea-Milla; Alfonso Serrano; Miguel Morell
Journal:  Hum Pathol       Date:  2003-12       Impact factor: 3.466

8.  Changing trends. An overview of breast cancer incidence and mortality.

Authors:  L Garfinkel; C C Boring; C W Heath
Journal:  Cancer       Date:  1994-07-01       Impact factor: 6.860

9.  Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.

Authors:  Lisa K Dunnwald; Mary Anne Rossing; Christopher I Li
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

10.  Association between high-risk HPV types, HLA DRB1* and DQB1* alleles and cervical cancer in British women.

Authors:  J Cuzick; G Terry; L Ho; J Monaghan; A Lopes; P Clarkson; I Duncan
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

View more
  4 in total

1.  HLA alleles in breast cancer.

Authors:  Ozlem Goruroglu Ozturk
Journal:  Pathol Oncol Res       Date:  2012-10       Impact factor: 3.201

2.  Relationship between HLA-DRB1 gene polymorphism and breast cancer: A protocol for systematic review and meta-analysis.

Authors:  Linlin Liu; Xu Sun; Chenxi Yuan; Huaimin Liu
Journal:  Medicine (Baltimore)       Date:  2021-03-26       Impact factor: 1.817

3.  Indomethacin enhances anti-tumor efficacy of a MUC1 peptide vaccine against breast cancer in MUC1 transgenic mice.

Authors:  Jennifer M Curry; Dahlia M Besmer; Timothy K Erick; Nury Steuerwald; Lopamudra Das Roy; Priyanka Grover; Shanti Rao; Sritama Nath; Jacob W Ferrier; Robert W Reid; Pinku Mukherjee
Journal:  PLoS One       Date:  2019-11-06       Impact factor: 3.240

4.  Relevance of the MHC region for breast cancer susceptibility in Asians.

Authors:  Mikael Hartman; Jingmei Li; Peh Joo Ho; Alexis Jiaying Khng; Benita Kiat-Tee Tan; Ern Yu Tan; Su-Ming Tan; Veronique Kiak Mien Tan; Geok Hoon Lim; Kristan J Aronson; Tsun L Chan; Ji-Yeob Choi; Joe Dennis; Weang-Kee Ho; Ming-Feng Hou; Hidemi Ito; Motoki Iwasaki; Esther M John; Daehee Kang; Sung-Won Kim; Allison W Kurian; Ava Kwong; Artitaya Lophatananon; Keitaro Matsuo; Nur Aishah Mohd-Taib; Kenneth Muir; Rachel A Murphy; Sue K Park; Chen-Yang Shen; Xiao-Ou Shu; Soo Hwang Teo; Qin Wang; Taiki Yamaji; Wei Zheng; Manjeet K Bolla; Alison M Dunning; Douglas F Easton; Paul D P Pharoah
Journal:  Breast Cancer       Date:  2022-05-11       Impact factor: 3.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.